Marijuana Company Cronos Reduces FY23 Net Loss As It Utilizes Global Expansion

Cronos Group Inc. CRON CRON released its 2023 fourth quarter and full-year business results Thursday with quarterly revenue of $23.9 million, up by $1.9 million from the same quarter of 2022.

"In 2023, we significantly improved our cash flow from operations driven primarily by operating expense savings, while simultaneously expanding our portfolio of borderless products in Canada and Israel and entering two international markets, Germany and Australia," stated Mike Gorenstein, chairman, president and CEO of Cronos."The operating expense savings combined with robust interest income and improved working capital management in the fourth quarter aided in increasing our cash balance by $22 million from the third quarter to a total cash and short-term investments balance of approximately $862 million."

After successfully expanding across Canada and Israel, Cronos entered new markets – Germany and Australia. Last year, the company exited U.S. hemp-derived CBD operations. Cronos noted at the time it had made this decision to improve its cash flow in the near term and position itself to directly enter the U.S. THC market when the necessary changes in U.S. regulatory conditions occur. In 2023, it also launched the Lord Jones brand in the Canadian market.

Q4 Financial Summary 

  • Gross profit of $1.9 million in Q4 2023 increased by $700,000 from Q4 2022.
  • Adjusted EBITDA was a loss of $(14.8) million in Q4 2023, but improved by $4.2 million from the same quarter in the prior year.
  • Net loss of $(45) million, compares to net loss of $(78.9) million in the same quarter of 2022.
  • Net loss per share was $(0.12), which compares to net loss per share of $(0.21) in Q4 of 2022.

Full-Year 2023

  • Net revenue of $87.2 million increased by $500,000 from full-year 2022.
  • Gross profit of $11.9 million decreased by $3.5 million from full-year 2022. 
  • Adjusted EBITDA was a loss of $(61.6) million in full-year 2023 but improved by $8.7 million from full-year 2022. 
  • Net loss amounted to $(74.6) million, compared to net loss of $(168.73) million in 2022. 
  • Net loss per share was $(0.19), which compares to a net loss per share of $(0.45) for the full year 2022. 

Price Action

Cronos shares traded 0.51% lower at $2.25 per share during Thursday's pre-market session. 

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world. Get your tickets now on bzcannabis.com – Prices will increase very soon!

Photo: Courtesy of HTWE via Shutterstock 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsCannabis EarningsMike Gorenstein
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.